173 related articles for article (PubMed ID: 20946206)
1. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
Kwon YD; Ohe JY; Kim DY; Chung DJ; Park YD
Clin Oral Implants Res; 2011 Jan; 22(1):100-5. PubMed ID: 20946206
[TBL] [Abstract][Full Text] [Related]
2. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Kwon YD; Kim DY; Ohe JY; Yoo JY; Walter C
J Oral Maxillofac Surg; 2009 Dec; 67(12):2644-8. PubMed ID: 19925985
[TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
4. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
5. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
[No Abstract] [Full Text] [Related]
7. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
Lee CY; Suzuki JB
Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
[TBL] [Abstract][Full Text] [Related]
8. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and bisphosphonate induced osteonecrosis.
Sawatari Y; Marx RE
Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
[TBL] [Abstract][Full Text] [Related]
10. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
[TBL] [Abstract][Full Text] [Related]
11. Management of bisphosphonate-induced osteonecrosis of the jaw.
Schilling J
Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
[TBL] [Abstract][Full Text] [Related]
12. Serum CTX testing.
Schwartz HC
J Oral Maxillofac Surg; 2008 Jun; 66(6):1319-20; author reply 1320. PubMed ID: 18486810
[No Abstract] [Full Text] [Related]
13. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
Dello Russo NM; Jeffcoat MK; Marx RE; Fugazzotto P
Int J Oral Maxillofac Implants; 2007; 22(1):146-53. PubMed ID: 17340909
[No Abstract] [Full Text] [Related]
14. Osteonecrosis of the jaw and biomarkers: what do we tell our patients?
Koka S
Int J Oral Maxillofac Implants; 2008; 23(2):179-80. PubMed ID: 18548914
[No Abstract] [Full Text] [Related]
15. Bisphosphonates and the dental patient: Part 2.
Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
Compend Contin Educ Dent; 2007 Sep; 28(9):510-5; quiz 516, 528. PubMed ID: 17907374
[TBL] [Abstract][Full Text] [Related]
16. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Kwon YD; Kim DY
Oral Oncol; 2009 Sep; 45(9):839. PubMed ID: 19152792
[No Abstract] [Full Text] [Related]
17. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Bagan JV; Jiménez Y; Gómez D; Sirera R; Poveda R; Scully C
Oral Oncol; 2008 Nov; 44(11):1088-9. PubMed ID: 18396443
[TBL] [Abstract][Full Text] [Related]
18. CTX and its role in managing patients exposed to oral bisphosphonates.
Dodson TB
J Oral Maxillofac Surg; 2010 Feb; 68(2):487-8; author reply 488-9. PubMed ID: 20116729
[No Abstract] [Full Text] [Related]
19. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers.
Fleisher KE; Welch G; Kottal S; Craig RG; Saxena D; Glickman RS
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):509-16. PubMed ID: 20674404
[TBL] [Abstract][Full Text] [Related]
20. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Chiu CT; Chiang WF; Chuang CY; Chang SW
J Oral Maxillofac Surg; 2010 May; 68(5):1055-63. PubMed ID: 20403529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
